SEC Form 4 · accession 0000899243-18-008514

Odonate Therapeutics, Inc. · ODT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners

10% Owner

10% Owner

Director · 10% Owner

Period of report

Mar 22, 2018

Accepted (ET)

Mar 26, 2018 · 6:59 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001717452

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1,F2,F3	Mar 22, 2018	P	23,407	$20.94	A	2,750,345	D
Common Stock^F2,F3	Mar 23, 2018	P	42,943	$23.96	A	2,793,288	D
Common Stock^F2,F3	Mar 26, 2018	P	33,650	$22.41	A	2,826,938	D

No Table II lines on this filing.

F1The reporting person effected multiple same-way open market purchases on the same day at different prices through multiple trade orders. The price in the table reflects the weighted average purchase price of such trades on such date. These shares were purchased at prices ranging from $20.76 to $21.16 per share. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.
F2These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Aaron I. Davis, and (iv) Joseph C. Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein.
F3These securities are owned indirectly by Boxer Management and Joseph Lewis, by virtue of their ownership of Boxer Capital.